<DOC>
	<DOCNO>NCT00535132</DOCNO>
	<brief_summary>The purpose study evaluate medication satisfaction least 4 week paliperidone ER ( extended-release ) , antipsychotic , treatment patient schizophrenia previously take either 4 6 mg risperidone daily mouth , satisfied treatment .</brief_summary>
	<brief_title>Study Measure Drug Satisfaction Patients With Schizophrenia After Switching From Risperidone Paliperidone</brief_title>
	<detailed_description>Paliperidone ER show effective compare placebo ( `` sugar pill '' ) acute treatment maintenance patient schizophrenia . Paliperidone ER combine active metabolite another antipsychotic , risperidone , manufacture technology allow gradual release drug less difference high low blood level drug . Side effect medication sometimes due wide difference high low blood level . Recent research show many patient schizophrenia discontinue antipsychotic medication due `` subject-choice '' . Therefore , important research study attempt measure patient ' satisfaction antipsychotic medication , addition measure respond test effectiveness . This study design evaluate antipsychotic medication satisfaction patient continue symptom schizophrenia , say dissatisfied current risperidone treatment . The primary outcome change Medication Satisfaction Questionnaire ( MSQ ) score , baseline Week 6 endpoint . These patient randomize ( like flip coin ) risperidone ( 4 mg 6 mg per day ) switch paliperidone ER . Because study 'blinded ' , neither study doctor patient know treatment risperidone stop treatment paliperidone ER begin . Throughout study patient continue receive antipsychotic medication daily . Patients continue daily dose risperidone randomly assign switch paliperidone ER . All patient switch paliperidone ER course study switch continue take paliperidone ER remainder study . Paliperidone ER start 6 mg/day increase 9 mg/day 12 mg/day doctor 's discretion . Effectiveness safety measure visit schedule weekly first four week Week 6 endpoint . At visit , patient ask complete psychiatric test questionnaire measure effectiveness patient satisfaction medicine . They also complete test evaluation safety , include electrocardiogram ( ECGs , electrical tracing heart ) blood sample begin end study . Each patient receive two blind capsule mouth daily morning 6 week . Patients take risperidone receive either 4-mg 6-mg capsule plus placebo capsule . When patient switch , Paliperidone ER start 6 mg/day day risperidone discontinue increased 9 mg/day 12 mg/day doctor 's discretion . Paliperidone 3-mg 6-mg capsule combine placebo equal total dose two capsule .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Must able understand , opinion investigator , informed consent form . diagnose schizophrenia report dissatisfaction current medication aspect schizophrenia management could potentially benefit change antipsychotic medication receive risperidone 4 mg 6 mg least 4 week start study . Unable swallow study drug whole aid water receive investigational drug , use investigational medical device , participate clinical study alter medication within 6 month first administration study drug , participate 2 investigational drug study within past 12 month major mental health diagnosis except tobacco dependance use cocaine heroin within 3 month first administration history treatment antipsychotic addition treatment risperidone , treatment paliperidone , within 30 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>medication satisfaction , Invega</keyword>
</DOC>